MAIO MICHELE

Contacts

Teaching activities

Completion accademic year: 2024/2025

Course year: 6 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2019/2020
Course year: 6 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2019/2020

Completion accademic year: 2023/2024

Course year: 6 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2018/2019
Course year: 1 NUTRITIONAL SCIENCE A.Y. 2023/2024
Course year: 1 NUTRITIONAL SCIENCE A.Y. 2023/2024
Course year: 6 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2018/2019

Completion accademic year: 2022/2023

Course year: 2 EMATOLOGIA A.Y. 2021/2022
Course year: 3 EMATOLOGIA A.Y. 2020/2021
Course year: 1 RADIODIAGNOSTICS A.Y. 2022/2023
Course year: 1 GINECOLOGIA ED OSTETRICIA A.Y. 2022/2023

Research

Ultime pubblicazioni:

  • Di Giacomo, A.M., Lahn, M., Eggermont, A.M., Fox, B., Ibrahim, R., Sharma, P., et al. (2024). The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?. EUROPEAN JOURNAL OF CANCER, 198 [10.1016/j.ejca.2023.113501]. - view more
  • Simonetti, E., Cutarella, S., Valente, M., Sani, T., Ravara, M., Maio, M., et al. (2023). From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma. ONCOTARGETS AND THERAPY, 16, 227-232 [10.2147/OTT.S368408]. - view more
  • Cusi, M.G., Di Giacomo, A.M., Anichini, G., Gori Savellini, G., Terrosi, C., Gandolfo, C., et al. (2023). Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID. VIRUSES, 15(3), 614 [10.3390/v15030614]. - view more
  • Strauss, J., Deville, J., Sznol, M., Ravaud, A., Maruzzo, M., Pachynski, R.K., et al. (2023). First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 11(5) [10.1136/jitc-2022-005813]. - view more
  • Yadavilli, S., Waight, J.D., Brett, S., Bi, M., Zhang, T., Liu, Y., et al. (2023). Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. CANCER RESEARCH COMMUNICATIONS, 3(8), 1564-1579 [10.1158/2767-9764.CRC-22-0293]. - view more